Background

For patients with muscle-invasive bladder cancer (MIBC), the current standard treatment is chemotherapy followed by surgery to remove the bladder. Unfortunately, even with this aggressive approach, about half of patients see their cancer return. Recently, new drugs called immunotherapies have shown promise in treating advanced bladder cancer. These treatments help the body’s immune system recognize and attack cancer cells. However, scientists still don’t fully understand how chemotherapy—and especially chemotherapy combined with immunotherapy—changes the immune system in bladder cancer patients. 

What This Research Proposes to Address

Bladder cancers can be grouped into two main subtypes called “luminal” and “basal.” Luminal tumors usually have fewer immune cells around them at first. But researchers have noticed that after chemotherapy, some luminal tumors become more filled with immune cells, as though the body is mounting an immune attack. They believe these immune cells may be targeting certain proteins on the tumor called antigens. Prior studies also suggest that luminal tumors may respond better to immunotherapy. 

This project will study how chemotherapy alone, and chemotherapy combined with immunotherapy, affect the immune system in patients with MIBC. Researchers will use blood and tumor samples collected from patients in an ongoing clinical trial to carefully track these immune changes. 

Why This Research Is Important

If scientists can confirm that luminal tumors respond strongly to the combination of chemotherapy and immunotherapy, it could change how doctors treat bladder cancer. Understanding these immune responses may help identify which patients will benefit most from combined treatment. The goal is to improve cure rates for MIBC. 

Final Summary Report

For patients with muscle-invasive bladder cancer (MIBC), treatment usually involves chemotherapy followed by surgery to remove the bladder. Sadly, about half of patients still see their cancer return after this approach. New drugs called immunotherapies, which help the immune system attack cancer, have shown success in advanced bladder cancer. But doctors don’t yet fully understand how chemotherapy alone—or chemotherapy combined with immunotherapy—changes the immune system in MIBC. 

Researchers have discovered that bladder cancers can be divided into two groups, called “luminal” and “basal” subtypes. At first, luminal tumors have fewer immune cells. However, this study found that after chemotherapy, luminal tumors often attract more immune cells, and those immune cells may be reacting to tumor proteins known as antigens. This suggests that luminal tumors might respond especially well when chemotherapy is combined with immunotherapy. 

To test this, the research team launched a clinical trial using chemotherapy together with an immunotherapy drug called pembrolizumab. When the study is complete, they will compare the immune responses of patients who received chemotherapy alone with those who had the combined treatment. The goal is to learn which patients are most likely to benefit from the combined approach, leading to more effective and personalized care. 

None Reported as of August 2025

None Reported as of August 2025

NA